AI For Pharma Growth

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr Eugene Chan of Behavieural about why many AI failures in pharma are not really technical failures at all. They are human problems involving trust, judgement, behaviour and adoption.Eugene explains that even when the technology works, people may ignore it, override it or over-trust it. Clinicians, scientists and executives bring their own biases, habits, incentives and sense of professional identity to every AI-assisted decision.The conversation explores why autonomy matters, how cognitive load changes behaviour, and why one incorrect AI output can damage trust far beyond that single mistake. Eugene also discusses automation bias, the risks of simply clicking approve, and why explainability needs to help judgement rather than replace it.They also look at change management and why one-off training is not enough. If organisations want AI adoption to stick, behavioural interventions need to become part of workflow design, governance and organisational culture.The key message is that having the best model, policy or governance framework is not enough if it assumes people will behave rationally.Behavieural - https://behavieural.com/ Topics CoveredWhy pharma AI adoption is a behavioural problemTrusting and distrusting AIAutomation bias and over-relianceProfessional identity and autonomyCognitive load and decision makingWhy one bad output can damage long-term trustHuman judgement versus AI recommendationsChange management and behaviour changeDesigning governance around real human behaviourAbout EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.comAbout the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.Dr. Andree Bates LinkedIn | Facebook | X

In this solo episode of AI For Pharma Growth, Dr Andree Bates explores what health technology assessment bodies now expect when AI is used to generate, analyse or support evidence.The episode looks at the emerging principles from NICE in England, CDA-AMC in Canada and the EU Joint Clinical Assessment framework. While none of these bodies has banned AI, Andree explains that organisations are increasingly expected to be able to justify where AI was used, how it was used, who was responsible for checking it and whether the process can be reconstructed.She breaks the expectations into four core areas: accountability, human oversight, transparency and reporting. That includes recording tools, versions, dates, prompts, adaptations and the specific role AI played in screening, extraction, analysis or reporting.Andree also highlights one of the biggest practical risks: automation bias. Human oversight cannot simply mean somebody glanced at the output. It means having a named person who can explain what was checked, how it was checked and why the level of verification was appropriate for that task.The key message is that AI can still accelerate evidence generation, but teams now need the documentation and governance to defend its use.Topics CoveredNICE, CDA-AMC and EU JCA expectationsAccountability for AI-assisted evidenceHuman oversight and automation biasDeclaring AI tools and methodsRecording prompts, versions and outputsScreening versus extraction riskCopyright, data protection and securityAI use across vendors and CROsBuilding an audit trail before submissionWhat assessors may ask nextAbout EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.comAbout the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.Dr. Andree Bates LinkedIn | Facebook | X

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Mattia Marco Caruson, co-founder and CEO of mama health, about how generative AI is changing the way pharma understands the patient journey.Mattia explains why traditional methods such as surveys, focus groups and clinician interviews often capture only fragments of what patients actually experience. In rare and chronic diseases, the most important parts of the journey can happen between appointments, long before a patient reaches the right doctor or treatment.The conversation explores how generative AI can enable open-ended conversations with patients at scale and then turn those qualitative stories into structured, analysable data. Instead of forcing people to reduce years of lived experience to a multiple-choice answer, AI can help capture their own words, frustrations, unmet needs and decision points.Mattia also discusses how these insights can influence launch strategy, positioning, patient support, medical affairs and market access. He argues that pharma should stop viewing AI only as a way to make existing processes faster and start asking what entirely new capabilities it unlocks.They also examine consent, privacy, hallucination risk and the need to ground patient-facing AI in trusted medical sources.Topics CoveredWhy surveys miss important parts of the patient journeyAI-powered patient conversations at scaleTurning qualitative stories into structured insightUnderstanding unmet needs and treatment decisionsPatient insight for launch and commercial strategyConsent, privacy and data governanceGrounding AI in trusted medical knowledgeWhy pharma needs to listen directly to patientsAbout EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.comAbout the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.Dr. Andree Bates LinkedIn | Facebook | X

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr. Kurt Rohloff, co-founder and CEO of Duality Technologies, about how privacy-enhancing technologies could unlock data collaboration without forcing organisations to give up control of sensitive information.Kurt explains how technologies such as fully homomorphic encryption and federated learning allow organisations to analyse encrypted or distributed data without exposing the underlying patient information. For pharma and medical research, that creates opportunities to reuse existing data, collaborate across organisations and geographies, and access populations that have historically been difficult to include.The conversation explores why data security should not be viewed only as a compliance cost. Secure collaboration can also become a value creator, helping organisations run better science, reduce administrative overhead and generate evidence that would otherwise be too expensive or difficult to obtain.They also discuss rare diseases, underserved communities, cross-border research and the role regulators and standards bodies will play in enabling wider adoption. Kurt argues that the technology is often further ahead than organisational acceptance, making policy conversations just as important as technical development.Topics CoveredPrivacy-enhancing technologies in pharmaFully homomorphic encryptionFederated learning and secure analyticsReusing clinical and research dataCross-border collaborationRare diseases and underserved populationsData sovereignty and regulatory acceptanceSecure AI and LLM workloadsAbout EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.comAbout the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.Dr. Andree Bates LinkedIn | Facebook | X

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Clara Bernardes, co-founder and CSO of Biorce, about how AI can accelerate clinical development without sacrificing compliance or scientific rigour.Biorce was born from a deeply personal experience. After Clara's father-in-law received a terminal melanoma diagnosis, access to a clinical trial through compassionate use extended his life from an expected three months to more than a year. That experience shaped Biorce's mission: reduce the time it takes promising treatments to reach patients.Clara explains why clinical trials are still slowed by protocol amendments, patient identification problems, poorly designed criteria and human-led errors that could often be caught much earlier.The conversation explores how Biorce uses AI and almost one million annotated protocols to support protocol development, learn from previous trial amendments and provide clear rationale for recommendations. Clara also discusses why transparency, AI ethics and keeping humans in the loop are essential in regulated clinical development.The key message is that speed and compliance do not have to be opposing forces. The goal is not to replace scientists or investigators, but to give them better information faster while preserving human judgement.Topics CoveredWhy clinical trials start lateProtocol amendments and avoidable human errorAI-generated clinical trial protocolsLearning from previous trial failuresTransparency and explainabilityAI ethics and regulatory complianceKeeping humans in the loopBalancing quality with velocityWhat sponsors should ask AI vendorsAbout EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.comAbout the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.Dr. Andree Bates LinkedIn | Facebook | X

In this solo episode of AI For Pharma Growth, Dr Andree Bates explores one of the biggest blind spots in pharma AI: the failures that can survive a normal review process even when the output sounds polished, plausible and well grounded.Dr Andree explains why better models and better retrieval do not remove the need for human judgement. In fact, as AI systems improve, people often scrutinise them less. Fluent prose can create a false sense of reliability, while automation bias and anchoring make reviewers less likely to challenge the underlying frame.The episode introduces three broad families of failure: invented, distorted and misdirected. These include fabricated or misattributed citations, silent interpolation, dropped qualifiers, hedge-to-claim escalation, manufactured consensus, stale guidance and planted instructions. Many of these are harder to catch because the output reads better than the truth.Dr Andree also shares practical checks teams can use, including tracing claims back to source, checking what is unsupported, looking for missing qualifiers, regenerating outputs for stability and deliberately testing the opposite case.The key message is that prompting is only half the skill. In a regulated industry, teams also need to be trained to judge what comes back.Topics CoveredWhy better AI can lead to less scrutinyAutomation bias and anchoringInvented, distorted and misdirected failuresFabricated and misattributed citationsDropped qualifiers and strengthened claimsManufactured consensusPrompt injection and planted instructionsClaim-by-claim verificationWhy review methods must change for AIThe growing importance of the judgement layerAbout EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.comAbout the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.Dr. Andree Bates⁠⁠ LinkedIn⁠⁠ |⁠⁠ Facebook⁠⁠ |⁠⁠ X

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with cancer biologist and health educator Rebecca Maff about how AI could help shift healthcare from treating disease to preventing it.Rebecca’s interest in prevention began after seeing women in her own family diagnosed with late-stage cancers and serious autoimmune conditions. Her subsequent work has included machine learning models designed to identify patients at higher risk of cancers and encourage overdue screening before disease progresses.The conversation explores what prevention really means in practice, from early biomarkers and personalised risk modelling to screening, lifestyle, metabolic health and behavioural change. Rebecca explains how AI can help analyse electronic health records and large patient populations to identify signals that would be difficult for humans to find manually.They also discuss the commercial opportunity for pharma. If late-stage disease becomes more preventable, the industry may need to think beyond treating established illness and consider new models built around earlier detection, intervention and maintaining health.Trust remains a major challenge. Rebecca argues that patients and clinicians need to see credible, successful AI implementations before confidence grows, particularly when systems are using highly personal health, genomic and behavioural data.Topics CoveredMoving healthcare upstream towards preventionAI-powered cancer risk stratificationEarly screening and disease detectionBiomarkers and personalised riskUsing electronic health records to identify signalsPrevention as a future pharma opportunityLifestyle, metabolic health and chronic diseasePatient data, privacy and trust in AIWhy proof of concept matters before scalingAbout EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.comAbout the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.Dr. Andree Bates LinkedIn | Facebook | X

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Raviv Pryluk, co-founder and CEO of PhaseV, about why so many clinical trials still fail and where AI can genuinely improve the odds.Raviv argues that failure is often not because the drug itself is wrong. Trials can fail because of the wrong patient population, indication, dose, design, sites, monitoring or interpretation of the data. PhaseV uses causal machine learning, adaptive trial design and large-scale simulation to help sponsors make better decisions across those areas.The conversation explores why explainability and validation matter in clinical development. Raviv explains that a 95% prediction is not enough on its own. Sponsors and regulators need to understand why a recommendation is being made, which evidence supports it, and whether the result is statistically and clinically defensible.They also discuss using existing trial data to identify responder subgroups, stress-testing designs before patients are enrolled, adapting trials mid-flight and connecting protocol design more closely with clinical operations.Topics CoveredWhy clinical trials still failCausal ML versus predictive modellingPatient selection and responder subgroupsAdaptive trial designSimulating trials before enrolmentSite selection and recruitmentValidation, explainability and statistical guaranteesGo/no-go portfolio decisionsAbout EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.comAbout the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.Dr. Andree Bates⁠⁠ LinkedIn⁠⁠ |⁠⁠ Facebook⁠⁠ |⁠⁠ X

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dan Pratl, founder and CEO of Quadron Inc, about a trust problem emerging as AI moves deeper into pharma: how do organisations preserve confidence when more work is generated, shaped and accelerated by machines?Dan argues that verified output alone is not enough. Pharma already has human review, MLR, regulatory sign-off and quality controls, but trust also depends on understanding where data came from, which models were used, where human judgement entered the process and whether that chain can be audited.The conversation explores why human expertise may become more valuable, not less, as AI spreads. Dan discusses shadow AI, the limits of forcing employees onto a single approved model, and why organisations need to reward people for curating, verifying and applying judgement across tools rather than treating AI usage itself as productivity.They also examine the risk of losing the junior work that traditionally builds expertise, the need for stronger audit trails, and why redesigning systems around AI may matter more than simply adding another governance dashboard.Topics CoveredAI and pharma's emerging trust problemWhy verified output is not the whole answerHuman judgement as a scarce resourceShadow AI and unsanctioned modelsAudit trails across humans, models and dataThe danger of equating token use with productivityBuilding future expertise in an AI-enabled workforceWhy trust requires incentives as well as governanceAbout EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.comAbout the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.Dr. Andree Bates LinkedIn | Facebook | X

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr. Jacek Marczyk, co-founder and CEO of BioDynLab, about a contrarian view of computational drug discovery: that the next leap may come not from more data and bigger models, but from physics.Dr. Marczyk brings a background in aerospace engineering, automotive, Silicon Graphics and complexity science. His work led to quantitative complexity theory, which he now applies to molecules through BioDynLab’s deterministic, training-free approach.The conversation explores why high precision and high complexity cannot coexist, and why throwing more compute at biological problems does not automatically produce useful knowledge. Dr. Marczyk argues that machine learning can produce impressive outputs, but without explainability, teams may get a result without understanding the physics behind it.He explains how BioDynLab uses molecular dynamics and complexity theory to study how atoms and amino acids move, how information flows through molecules, and which residues act as key “hotspots” in that dynamic system. Instead of treating molecules as static structures, this approach looks at the motion and information patterns that help determine biological function.The key message is that AI and physics should not be seen as enemies. In data-sparse areas such as rare diseases, novel targets and first-in-class chemistry, physics-led methods may offer a complementary route to insight, especially where machine learning has little or no training data to rely on.Topics CoveredWhy pharma’s AI gold rush may miss key biologyThe principle of incompatibilityPhysics-first drug discoveryQuantitative complexity theoryWhy explainability mattersMolecular dynamics and information flowAtomic and amino acid participation factorsComplexity hotspots in moleculesStatic structures versus molecular motionRare disease and data-sparse discoveryAbout EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.comDr. Andree Bates⁠ LinkedIn⁠ |⁠ Facebook⁠ |⁠ X